MedTrace Logo

Phase 1 Study(Additional) of URC102 in Healthy Subjects

NCT02524678 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2020-02-13

No results posted yet for this study

Summary

The purpose of this study is to assess the safety, tolerability, PK and PD of URC102 in healthy subjects.

Conditions

  • Healthy

Interventions

DRUG

Placebo

DRUG

URC102

Sponsors & Collaborators

Principal Investigators

  • Howard Lee, MD, PhD · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
49 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-08-05
Primary Completion
2015-10-07
Completion
2016-03-28

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02524678 on ClinicalTrials.gov